New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - oxycodone hydrochloride 5mg equivalent to 4.5 mg of oxycodone base;   - modified release tablet - 5 mg - active: oxycodone hydrochloride 5mg equivalent to 4.5 mg of oxycodone base   excipient: ammonio methacrylate copolymer brilliant blue fcf hypromellose lactose monohydrate macrogol 400 magnesium stearate opadry blue 06b20843 povidone purified talc stearyl alcohol titanium dioxide triacetin - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoprostenol sodium 1.593mg equivalent to epoprostenol 1.5 mg - powder for injection - 1.5 mg - active: epoprostenol sodium 1.593mg equivalent to epoprostenol 1.5 mg excipient: arginine sodium hydroxide sucrose - veletri is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii and iv patients with: · idiopathic pulmonary arterial hypertension · familial pulmonary arterial hypertension · pulmonary arterial hypertension asscociated with the scleroderma spectrum of diseases.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - epoprostenol sodium 531ug equivalent to epoprostenol 500 mcg - powder for injection - 500 mcg - active: epoprostenol sodium 531ug equivalent to epoprostenol 500 mcg excipient: arginine sodium hydroxide sucrose - veletri is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii and iv patients with: · idiopathic pulmonary arterial hypertension · familial pulmonary arterial hypertension · pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - abacavir sulfate 702mg equivalent to abacavir 600 mg;  ;  ; lamivudine 300mg;   - film coated tablet - 600mg/300mg - active: abacavir sulfate 702mg equivalent to abacavir 600 mg     lamivudine 300mg   excipient: magnesium stearate microcrystalline cellulose opadry orange ys-1-13065a sodium starch glycolate - kivexa is a combination of two nucleoside analogues (abacavir and lamivudine). it is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - pantoprazole sodium sesquihydrate 22.55mg equivalent to 20 mg pantoprazole;  ;   - enteric coated tablet - 20 mg - active: pantoprazole sodium sesquihydrate 22.55mg equivalent to 20 mg pantoprazole     excipient: calcium stearate crospovidone mannitol methacrylic acid copolymer opadry yellow oy-52945 povidone purified water   sodium carbonate triethyl citrate - 1. for the symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: - duodenal ulcer

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - pantoprazole sodium sesquihydrate 45.1mg equivalent to pantoprazole 40 mg;  ;   - enteric coated tablet - 40 mg - active: pantoprazole sodium sesquihydrate 45.1mg equivalent to pantoprazole 40 mg     excipient: calcium stearate crospovidone mannitol methacrylic acid copolymer opadry yellow 02b520025 povidone purified water   sodium carbonate triethyl citrate - 1. for the symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: - duodenal ulcer

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - dapagliflozin propanediol monohydrate 12.3mg equivalent to dapagliflozin 10 mg;  ; metformin hydrochloride 1000mg (with 0.5% magnesium stearate);   - modified release tablet - 10mg/1000mg - active: dapagliflozin propanediol monohydrate 12.3mg equivalent to dapagliflozin 10 mg   metformin hydrochloride 1000mg (with 0.5% magnesium stearate)   excipient: carmellose sodium colloidal silicon dioxide crospovidone hypromellose lactose magnesium stearate microcrystalline cellulose opadry yellow 85f12372 - glycaemic control xigduo xr is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control when treatment with both dapagliflozin and metformin is appropriate (see sections 5.1 and 4.4 for available data on the combination therapy). prevention of hospitalisation for heart failure dapagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease to reduce the risk of hospitalisation for heart failure (see section 5.1 pharmacodynamic properties – clinical efficacy and safety). prevention of new or worsening nephropathy dapagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease for the prevention of new or worsening nephropathy (see section 5.1 pharmacodynamic properties – clinical efficacy and safety).

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - dapagliflozin propanediol monohydrate 12.3mg equivalent to dapagliflozin 10 mg;  ; metformin hydrochloride 500mg (with 0.5% magnesium stearate);   - modified release tablet - 10mg/500mg - active: dapagliflozin propanediol monohydrate 12.3mg equivalent to dapagliflozin 10 mg   metformin hydrochloride 500mg (with 0.5% magnesium stearate)   excipient: carmellose sodium colloidal silicon dioxide crospovidone hypromellose microcrystalline cellulose (ph302) hypromellose (2910) lactose magnesium stearate microcrystalline cellulose opadry pink 85f94333 - glycaemic control xigduo xr is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control when treatment with both dapagliflozin and metformin is appropriate (see sections 5.1 and 4.4 for available data on the combination therapy). prevention of hospitalisation for heart failure dapagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease to reduce the risk of hospitalisation for heart failure (see section 5.1 pharmacodynamic properties – clinical efficacy and safety). prevention of new or worsening nephropathy dapagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease for the prevention of new or worsening nephropathy (see section 5.1 pharmacodynamic properties – clinical efficacy and safety).

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - dapagliflozin propanediol monohydrate 6.15mg equivalent to dapagliflozin 5 mg;  ; metformin hydrochloride 1000mg (with 0.5% magnesium stearate);   - modified release tablet - 5mg/1000mg - active: dapagliflozin propanediol monohydrate 6.15mg equivalent to dapagliflozin 5 mg   metformin hydrochloride 1000mg (with 0.5% magnesium stearate)   excipient: carmellose calcium colloidal silicon dioxide crospovidone hypromellose lactose magnesium stearate microcrystalline cellulose opadry pink 85f94592 - glycaemic control xigduo xr is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control when treatment with both dapagliflozin and metformin is appropriate (see sections 5.1 and 4.4 for available data on the combination therapy). prevention of hospitalisation for heart failure dapagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease to reduce the risk of hospitalisation for heart failure (see section 5.1 pharmacodynamic properties – clinical efficacy and safety). prevention of new or worsening nephropathy dapagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease for the prevention of new or worsening nephropathy (see section 5.1 pharmacodynamic properties – clinical efficacy and safety).

Australia - English - Department of Health (Therapeutic Goods Administration)

neolife international pty ltd - glycine max, quantity: 225 mg (equivalent: linolenic acid, qty 16.65 mg); triticum aestivum, quantity: 150 mg (equivalent: gluten, qty 0 mg); triticum aestivum, quantity: 10 mg (equivalent: gluten, qty 0.004 mg); oryza sativa, quantity: 300 mg; oryza sativa, quantity: 10 mg; mixed (high-alpha type) tocopherols concentrate, quantity: 2 mg - capsule, soft - excipient ingredients: gelatin; yellow beeswax; titanium dioxide; chlorophyllin-copper complex; purified water; glycerol - antioxidant/reduce free radicals formed in the body ; maintain/support body metabolism/metabolic rate ; maintain/support energy production ; maintain/support eye health ; maintain/support healthy teeth ; anti-inflammatory/relieve inflammation ; maintain/support connective tissue health ; helps enhance/promote bone health ; maintain/support bone health ; helps enhance/promote healthy joint function ; maintain/support joint health ; maintain/support cardiovascular system health ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; maintain/support immune system health ; maintain/support healthy immune system function ; maintain/support muscle health ; maintain/support muscle function ; helps maintain/support cellular uptake of (state vitamin/mineral/nutrient) ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; maintain/support brain function ; maintain/support nervous system health ; maintain/support nervous system function